EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Systemic angiogenic protein changes following propranolol therapy in infantile hemangioma: a multi-target perspective

Lijun Liang, Yan Zhang, Yan Ma, Jing Liu, Wangnan Du, Qiang Ma

Frontiers in Pharmacology · 19.12.2025 · 16

DOI: 10.3389/fphar.2025.1706048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.12.2025. Verfasst von Lijun Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, General Hospital of Ningxia Medical University, Yinchuan, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Infantile hemangioma (IH) is a common benign vascular tumor in infants, often requiring intervention due to potential functional impairment and cosmetic concerns. Propranolol, a nonselective β-adrenergic receptor blocker, is the first-line therapy for IH, yet its mechanisms remain incompletely elucidated.

Methods

This prospective study investigated the systemic angiogenic protein profile changes in response to propranolol in 14 treatment-naïve IH infants compared to 14 healthy controls using antibody array analysis.

Results

We identified twenty-six angiogenic proteins significantly downregulated in pretreatment IH patients compared to healthy controls. After 3 months of propranolol treatment, six proteins including HB-EGF, TGFα, ANGPTL4, Follistatin, Tie-1 and PLGF were significantly upregulated. Bioinformatic enrichment analysis revealed that these proteins are involved in key biological processes and signaling pathways, including epithelial cell proliferation, angiogenesis regulation, VEGF signaling, ERBB-EGFR axis, Ras-MAPK, and PI3K-Akt pathways.

Discussion

These results suggest that propranolol treatment is associated with a rebalancing of dysregulated angiogenic proteins in IH, through modulating both pro- and anti-angiogenic factors to rebalance vascular homeostasis. Our study provides novel insights into the systems-level pharmacological actions of propranolol and proposes potential biomarkers for treatment response evaluation.

Schlagwörter

Stichwörter der Autor:innen

angiogenesisbiomarkersinfantile hemangiomapropranololsignaling pathways

Autor:innen und Institutionen

  • Department of Pediatrics, General Hospital of Ningxia Medical University, Yinchuan, China.
  • Ningxia Health Vocational and Technical College, Shizuishan, China.
  • Graduate School, Dalian Medical University, Liaoning, China.
  • The First Clinical Medical College of Ningxia Medical University, Yinchuan, China.

Zitieren

APA

Liang, L., Zhang, Y., Ma, Y., Liu, J., Du, W., & Ma, Q. (2025). Systemic angiogenic protein changes following propranolol therapy in infantile hemangioma: a multi-target perspective. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1706048

Vancouver

Liang L, Zhang Y, Ma Y, Liu J, Du W, Ma Q. Systemic angiogenic protein changes following propranolol therapy in infantile hemangioma: a multi-target perspective. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1706048

BibTeX
@article{Liang2025,
  author = {Liang, Lijun and Zhang, Yan and Ma, Yan and Liu, Jing and Du, Wangnan and Ma, Qiang},
  title = {Systemic angiogenic protein changes following propranolol therapy in infantile hemangioma: a multi-target perspective},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1706048}
}
Kostenlos starten →